Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Livsstilsmønstre og glykæmisk kontrol

17. september 2026 opdateret af: Marie-Pierre St-Onge, Columbia University

The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.

The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide.

This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

15

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University Irving Medical Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

25 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
  • 25 years or older
  • BMI between 25-39.9 kg/m2
  • Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
  • Variable bedtime, SD≥45 minutes.

Exclusion Criteria:

  • Chronic Kidney Disease (GFR<60)
  • Uncontrolled hypertension (≥160/100 mmHg)
  • Obstructive Sleep Apnea
  • Psychiatric or neurological disorder
  • Prevalent cardiovascular disease
  • Dyslipidemia (triglycerides≥200 mg/dL)
  • Medications that affect insulin sensitivity, glucose concentrations, and body weight
  • Non-day or rotating shift workers
  • Travel across time zones
  • Active participation in weight loss program or within past 3 months
  • Current or past alcohol/drug abuse

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Støttende pleje
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Variable Schedule

Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks.

Eksperimentel: Fixed Schedule

Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks.

Participants will be asked to maintain a fixed schedule for 12 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Adipose Tissue Measurement - Total
Tidsramme: 12 weeks

Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue.

12 weeks
Adipose Tissue Measurement - Subcutaneous
Tidsramme: 12 weeks

Measurement of subcutaneous adiposity using MRI.

12 weeks
Adipose Tissue Measurement - Visceral
Tidsramme: 12 weeks

Measurement of visceral adiposity using MRI.

12 weeks
Glucose Area Under Curve
Tidsramme: 12 weeks

Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test.

12 weeks
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
Tidsramme: 12 weeks

Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose.

12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Liver Fat Content
Tidsramme: 12 weeks

This is to assess liver fat measured by MRS and MRI in %.

12 weeks
Disposition Index
Tidsramme: 12 weeks

This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance.

12 weeks
Short-term Change in Glycemia
Tidsramme: Baseline, up to 12 weeks

Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests.

Baseline, up to 12 weeks
Endothelial cell inflammation (sub-set, n≤10)
Tidsramme: Baseline, 12 weeks

NF-κB nuclear fluorescence area for pilot study.

Baseline, 12 weeks
White blood cells
Tidsramme: Baseline, 12 weeks

Leukocytes and neutrophils

Baseline, 12 weeks
Long-term Change in Glycemia
Tidsramme: Baseline, 12 weeks

Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests.

Baseline, 12 weeks
Endothelial cell oxidative stress (sub-set, n≤10)
Tidsramme: Baseline, 12 weeks

redox sensitive fluorogenic probe fluorescence intensity for pilot study.

Baseline, 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Marie-Pierre St-Onge, Columbia University
  • Ledende efterforsker: Blandine Laferrere, Columbia University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. januar 2022

Primær færdiggørelse (Faktiske)

30. juni 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

25. januar 2022

Først indsendt, der opfyldte QC-kriterier

25. januar 2022

Først opslået (Faktiske)

4. februar 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

21. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • AAAT8914
  • R01DK128154 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .